Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
Department of Internal Medicine, Division of Geriatrics, Loyola University Medical Center, Hines, Illinois, USA.
Cancer Med. 2023 Feb;12(3):3460-3467. doi: 10.1002/cam4.5126. Epub 2022 Sep 9.
Anal squamous cell carcinoma patients often present with significant symptoms, including pain, bleeding, and obstructive symptoms. This requires palliation-directed therapy as a first-line treatment to alleviate symptoms. The proportion of patients receiving first-line palliative treatments is unknown. We aimed to study the factors associated with the use of first-line palliative treatments in stage II-IV anal squamous cell carcinoma patients.
We used the National Cancer Database to identify adult patients diagnosed with stage II-IV anal squamous cell carcinoma between 2004 and 2016. We performed univariable and multivariable logistic regression analysis to determine the clinical and sociodemographic variables associated with the utilization of palliative treatment in the first-line setting, including palliative radiotherapy, chemotherapy, surgery, and pain management.
Among 16,944 patients diagnosed with stage II-IV anal squamous cell carcinoma, only a small proportion of 492 (2.9%) required first-line palliative treatments to control symptoms. The majority of these patients received palliative radiotherapy (32%), followed by palliative surgery (25%), palliative chemotherapy (19%), combination therapies (14%), and pain management (10%). On multivariable analysis, higher stage disease, lower income, Medicare and Medicaid insurance, and life expectancy <6 months were associated with higher odds of use of first-line palliative therapy.
First-line use of palliative treatments to control symptoms is needed in a small proportion of anal squamous cell cancer patients. It was utilized in all stages, but it was most frequently observed in patients with stage IV disease and patients with <6 months life expectancy. First-line palliative therapy was also more frequent in lower-income patients and patients with Medicare and Medicaid insurance which highlights the disparities in anal cancer management.
肛门鳞状细胞癌患者常出现明显症状,包括疼痛、出血和阻塞症状。这需要以姑息治疗为一线治疗以缓解症状。接受一线姑息治疗的患者比例尚不清楚。我们旨在研究与 II-IV 期肛门鳞状细胞癌患者使用一线姑息治疗相关的因素。
我们使用国家癌症数据库确定 2004 年至 2016 年间诊断为 II-IV 期肛门鳞状细胞癌的成年患者。我们进行单变量和多变量逻辑回归分析,以确定与一线姑息治疗(包括姑息性放疗、化疗、手术和疼痛管理)相关的临床和社会人口统计学变量。
在 16944 例诊断为 II-IV 期肛门鳞状细胞癌的患者中,仅有 492 例(2.9%)需要一线姑息治疗来控制症状。这些患者大多接受姑息性放疗(32%),其次是姑息性手术(25%)、姑息性化疗(19%)、联合治疗(14%)和疼痛管理(10%)。多变量分析显示,较高的疾病分期、较低的收入、医疗保险和医疗补助保险以及预期寿命<6 个月与一线姑息治疗的使用几率较高相关。
一小部分肛门鳞状细胞癌患者需要使用一线姑息治疗来控制症状。姑息治疗在所有分期中均有应用,但在 IV 期疾病和预期寿命<6 个月的患者中更为常见。一线姑息治疗也更常见于低收入患者和医疗保险和医疗补助保险患者,这突出了肛门癌管理中的差异。